Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Global leader in therapeutic ultrasound and present in the market for more than 35...
Global leader in therapeutic ultrasound and pre...
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company ...
Iterum Therapeutics plc is an Ireland-based cli...
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel p...
Evogene (NASDAQ, TASE: EVGN) is a leading biote...
Ultrasonic Medical Mapping, Inc., (UMM) is headquartered in Bethesda, MD. The comp...
Ultrasonic Medical Mapping, Inc., (UMM) is head...
Intellia Therapeutics is a leading genome editing company focused on developing cu...
Intellia Therapeutics is a leading genome editi...
Novan, Inc. is a clinical development-stage biotechnology company focused on lever...
Novan, Inc. is a clinical development-stage bio...
uniQure is delivering on the promise of gene therapy -- single treatments with pot...
uniQure is delivering on the promise of gene th...
Join the National Investor Network and get the latest information with your interests in mind.